To assess the outcome of radiotherapy (RT) to all PSMA ligand positive metastases for patients with castrate-resistant prostate cancer (mCRPC).
A total of 42 patients developed oligometastatic mCRPC and received PSMA PET-guided RT of all metastases.
To assess the outcome of radiotherapy (RT) to all PSMA ligand positive metastases for patients with castrate-resistant prostate cancer (mCRPC).
A total of 42 patients developed oligometastatic mCRPC and received PSMA PET-guided RT of all metastases.